TAK
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Takeda to present Phase 2/3 IgGNITE results for investigational subcutaneous TAK-881 in primary immunodeficiency at ESID 2026Oct 16, 2026
- Takeda spinout Cerevance prepares to consult the FDA on next steps for its Parkinson's drug solengepras following Phase 3 resultsOct 11, 2026
- Takeda highlights late-stage oncology pipeline progress and solid tumor research at ESMO 2026, led by late-breaking Phase 3 data for arcotatug tavatecanSep 22, 2026
- FDA accepted Takeda's NDA for zasocitinib under Priority Review for moderate-to-severe plaque psoriasisSep 14, 2026
- The New England Journal of Medicine published Phase 3 results for Takeda's oral OX2R agonist oveporexton (ORZEYFUL) in narcolepsy type 1Sep 9, 2026